Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose Escalation and Dose-Expansion Study (vol 35, pg 157, 2017)

被引：0
|
作者：
Burris, Howard A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 358
页数：1
相关论文
共 50 条
  • [31] Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
    Yamamoto, Noboru
    Horiike, Atsushi
    Fujisaka, Yasuhito
    Murakami, Haruyasu
    Shimoyama, Tatsu
    Yamada, Yasuhide
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) : 489 - 496
  • [32] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
    Piha-Paul, Sarina Anne
    Hierro, Cinta
    Funk, Jens Oliver
    Gourlay, Steven
    Smith, Patrick
    Venetsanakos, Eleni
    Meric-Bernstam, Funda
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
    Piha-Paul, Sarina Anne
    Hierro, Cinta
    Boni, Valentina
    Moreno, Victor
    Hahn, Noah M.
    Bitting, Rhonda L.
    Bauer, Todd Michael
    Aggarwal, Rahul Raj
    Gourlay, Steven
    Smith, Patrick
    Venetsanakos, Eleni
    Meric-Bernstam, Funda
    Brameld, Ken
    Karr, Dane
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
    Paz-Ares, Luis G.
    Gomez-Roca, Carlos
    Delord, Jean-Pierre
    Cervantes, Andres
    Markman, Ben
    Corral, Jesus
    Soria, Jean-Charles
    Berge, Yann
    Roda, Desamparados
    Russell-Yarde, Fiona
    Hollingsworth, Simon
    Baselga, Jose
    Umana, Pablo
    Manenti, Luigi
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (28) : 3783 - 3790
  • [35] A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-β) receptor I kinase inhibitor (galunisertib) in combination with anti-PD-1 (nivolumab) in advanced refractory solid tumours
    Guba, S. C.
    Mukhopadhyay, S.
    Desaiah, D.
    Andre, V. A. M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
    L R Molife
    P C Fong
    L Paccagnella
    A H M Reid
    H M Shaw
    L Vidal
    H-T Arkenau
    V Karavasilis
    T A Yap
    D Olmos
    J Spicer
    S Postel-Vinay
    D Yin
    A Lipton
    L Demers
    K Leitzel
    A Gualberto
    J S de Bono
    British Journal of Cancer, 2010, 103 : 332 - 339
  • [37] A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
    Davis, S. Lindsey
    Eckhardt, S. Gail
    Diamond, Jennifer R.
    Messersmith, Wells A.
    Dasari, Arvind
    Weekes, Colin D.
    Lieu, Christopher H.
    Kane, Madeline
    Tan, Aik Choon
    Pitts, Todd M.
    Leong, Stephen
    ONCOLOGIST, 2018, 23 (12): : 1409 - +
  • [38] The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
    Molife, L. R.
    Fong, P. C.
    Paccagnella, L.
    Reid, A. H. M.
    Shaw, H. M.
    Vidal, L.
    Arkenau, H-T
    Karavasilis, V.
    Yap, T. A.
    Olmos, D.
    Spicer, J.
    Postel-Vinay, S.
    Yin, D.
    Lipton, A.
    Demers, L.
    Leitzel, K.
    Gualberto, A.
    de Bono, J. S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (03) : 332 - 339
  • [39] A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Shitara, Kohei
    Kojima, Takashi
    Yoshino, Takayuki
    Dontabhaktuni, Aruna
    Rebscher, Hans
    Tang, Shande
    Cosaert, Jan
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1253 - 1262
  • [40] A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Kohei Shitara
    Takashi Kojima
    Takayuki Yoshino
    Aruna Dontabhaktuni
    Hans Rebscher
    Shande Tang
    Jan Cosaert
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1253 - 1262
12345